Novo Nordisk’s semaglutide achieved explosive sales in 2023. Ozempic alone generated $13,892 million in sales for the year. But now that Hims & Hers has revealed plans to sell compounded semaglutide to the masses, questions arise about how the Dutch pharma giant will respond. 2023 was a banner year for the firm with its diabetes…